...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Best practice & research: Clinical haematology >Radioimmunotherapy in follicular lymphoma.
【24h】

Radioimmunotherapy in follicular lymphoma.

机译：滤泡性淋巴瘤的放射免疫治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The exquisite sensitivity of haematological malignancies to targeted radiation make Radioimmunotherapy (RIT) a theoretically attractive therapeutic approach. Furthermore, impressive results initially achieved by the pioneers in this field and more recently in larger studies have demonstrated the high clinical activity of RIT in follicular NHL (FL). For more than a decade clinical RIT of FL has been dominated by targeting the CD20 antigen and a number of pivotal clinical studies have resulted in the approval by the US FDA (Food and Drug Administration) of two radioimmunconjugates, (131)I-tositumomab (Bexxar) and (90)Y-ibritumomab (Zevalin). (90)Y-ibritumomab tiuxetan was subsequently approved within the EU in 2004 and more recently in the EU and in the US as a front line "consolidation" treatment in follicular NHL. Recent data have demonstrated that fractionated radioimmunotherapy targeting CD22 with (90)Y-epratuzumab tetraxetan achieved a high degree of durable complete responses in relapsed/refractory NHL. Despite the fact that these RIT agents clearly have unique non-cross reactive mechanisms of action with proven high clinical efficacy in patients resistant to both chemotherapy and rituximab, they have not been widely adopted by haemato-oncology community to date. This chapter reviews the progress that has been made in the development of clinical radioimmunotherapy in follicular lymphoma and suggest some guidelines to use it appropriately in first-line but also in the increasing number of patients emerging who are rituximab-refractory.
机译：血液恶性肿瘤对靶向放射线的出色敏感性使放射免疫疗法（RIT）成为理论上有吸引力的治疗方法。此外，该领域的先驱者最初取得的令人印象深刻的结果以及最近在较大的研究中取得的令人瞩目的结果表明，RIT在滤泡性NHL（FL）中具有很高的临床活性。十多年来，FL的临床RIT一直以CD20抗原为靶标，许多关键的临床研究已导致美国FDA（食品和药物管理局）批准了两种放射免疫偶联物（131）I-tositumomab（ Bexxar）和（90）Y-ibritumomab（Zevalin）。 （90）Y-ibritumomab tiuxetan随后在2004年在欧盟内获得批准，最近又在欧盟和美国获得了作为滤泡性NHL的一线“巩固”治疗方法。最近的数据表明，针对CD22的分级放射免疫疗法与（90）Y-依帕珠单抗四氧杂环丁烷在复发/难治性NHL中获得了高度的持久性完全应答。尽管这些RIT药物显然具有独特的非交叉反应作用机制，并且对化疗和利妥昔单抗均具有很高的临床疗效，但迄今尚未被血液肿瘤学界广泛采用。本章回顾了滤泡性淋巴瘤临床放射免疫疗法的发展进展，并提出了一些指导方针，以便在一线治疗中适当使用它，但也有越来越多的利妥昔单抗难治性患者出现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号